Updated recommendations for HER2 testing in the UK

Ellis, I.O., Bartlett, J.M.S., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., Pinder, S.E., Rhodes, A. and Walker, R. (2004) Updated recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 57(3), pp. 233-237. (doi: 10.1136/jcp.2003.007724)

Abstract

This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Bartlett, Prof John
• Authors: Ellis, I.O., Bartlett, J.M.S., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., Pinder, S.E., Rhodes, A., and Walker, R.
• Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• College/School: College of Medical Veterinary and Life Sciences
• Journal Name: Journal of Clinical Pathology
• ISSN: 0021-9746
• Copyright Holders: Copyright © 2004 by the BMJ Publishing Group Ltd and Association of Clinical Pathologists.
• First Published: First published in the Journal of Clinical Pathology 57(3):233-237
• Publisher Policy: Reproduced in accordance with the copyright policy of the publisher